ETHEX Corporation has expanded two previous voluntary recalls initially issued in 2008 to include more than 60 generic drug products at either the wholesale level or retail level as a safety precaution. The generic products may have been manufactured under conditions that “did not sufficiently comply with current Good Manufacturing Practices,” according to a press release issued by the FDA.
Some of the products, such as Dextroamphetamine Sulfate generally prescribed for narcolepsy and attention deficit disorder with hyperactivity, fell under an earlier recall due to defects such as oversized tablets delivering higher than labeled doses of medication. The expanded recall is to ensure that all defective products have been removed from the market.
Oversized tablets also plagued U.S. generic pharmaceutical group Actavis Totowa LLC, which recalled batches of Digitek last April. Digitek is commonly used in the treatment of various heart conditions.
ETHEX has recall notifications to wholesalers for several drugs and to pharmacy retailers for Hydromophone HCI and Metoprolol Succinate only. Hydromophone HCI is a analgesic drug from the opioid class drug often used as an alternative to morphine. Metoprolol Succinate is a medication used to treat several conditions related to the heart and blood vessels. A complete listing of medications recalled is available from the FDA.
Patients who have any of these medications in their possession are advised to continue taking them in accordance to their prescriptions, as suddenly stopping them could put patients at risk. Patients also should contact their health care provider if they experience any problems or have questions about their prescriptions.
Any wholesale or retail customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to firstname.lastname@example.org. Representatives are available Monday through Friday, 8 am to 5 pm CST.